Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 12/2003

01-12-2003 | Review

Regulation of adipocytokines and insulin resistance

Authors: M. Fasshauer, Dr. R. Paschke

Published in: Diabetologia | Issue 12/2003

Login to get access

Abstract

It has long been known that obesity and insulin resistance are linked. Recently, it has been shown that adipocytes secrete several proteins including tumour necrosis factor-α, interleukin-6, resistin, and adiponectin. Since several of these so-called adipocytokines influence insulin sensitivity and glucose metabolism profoundly, they might provide a molecular link between increased adiposity and impaired insulin sensitivity. Thiazolidinediones which decrease insulin resistance and are used in the treatment of Type 2 diabetes seem to mediate part of their insulin-sensitising effects via modulation of adipocytokine expression. Furthermore, hormones such as β-adrenergic agonists, insulin, glucocorticoids, and growth hormone might impair insulin sensitivity at least in part via up-regulation or down-regulation of adipocytokine synthesis. We summarise the current knowledge on how major adipocyte-secreted proteins are regulated by hormones and drugs influencing insulin sensitivity and discuss its implications for insulin resistance and obesity.
Literature
1.
Matthaei S, Stumvoll M, Kellerer M, Haring HU (2000) Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 21:585–618PubMed
2.
Saltiel AR (2000) The molecular and physiological basis of insulin resistance: emerging implications for metabolic and cardiovascular diseases. J Clin Invest 106:163–164PubMed
3.
Hauner H (2002) The mode of action of thiazolidinediones. Diabetes Metab Res Rev 18 [Suppl 2]:S10–S15
4.
Stumvoll M, Haring HU (2002) Glitazones: clinical effects and molecular mechanisms. Ann Med 34:217–224PubMed
5.
Reaven GM, Lithell H, Landsberg L (1996) Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334:374–381
6.
Klein J, Fasshauer M, Ito M, Lowell BB, Benito M, Kahn CR (1999) beta(3)-adrenergic stimulation differentially inhibits insulin signaling and decreases insulin-induced glucose uptake in brown adipocytes. J Biol Chem 274:34795–34802CrossRefPubMed
7.
Fasshauer M, Klein J, Kriauciunas KM, Ueki K, Benito M, Kahn CR (2001) Essential role of insulin receptor substrate 1 in differentiation of brown adipocytes. Mol Cell Biol 21:319–329CrossRefPubMed
8.
Fasshauer M, Klein J, Ueki K et al. (2000) Essential role of insulin receptor substrate-2 in insulin stimulation of Glut4 translocation and glucose uptake in brown adipocytes. J Biol Chem 275:25494–25501CrossRefPubMed
9.
Patti ME (1999) Nutrient modulation of cellular insulin action. Ann NY Acad Sci 892:187–203
10.
Kahn BB, Flier JS (2000) Obesity and insulin resistance. J Clin Invest 106:473–481PubMed
11.
Bluher M, Kratzsch J, Paschke R (2001) Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care 24:328–334PubMed
12.
Gerich JE (1998) The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 19:491–503PubMed
13.
Ward AM, Fall CH, Stein CE et al. (2003) Cortisol and the metabolic syndrome in South Asians. Clin Endocrinol 58:500–505CrossRef
14.
Rizza RA, Mandarino LJ, Gerich JE (1982) Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31:663–669PubMed
15.
Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R (1986) Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol 250:E269–E273PubMed
16.
Smith TR, Elmendorf JS, David TS, Turinsky J (1997) Growth hormone-induced insulin resistance: role of the insulin receptor, IRS-1, GLUT-1, and GLUT-4. Am J Physiol 272:E1071–E1079PubMed
17.
Thirone AC, Carvalho CR, Brenelli SL, Velloso LA, Saad MJ (1997) Effect of chronic growth hormone treatment on insulin signal transduction in rat tissues. Mol Cell Endocrinol 130:33–42CrossRefPubMed
18.
Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87–91PubMed
19.
Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665–668PubMed
20.
Stephens JM, Lee J, Pilch PF (1997) Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 272:971–976CrossRefPubMed
21.
Xu H, Uysal KT, Becherer JD, Arner P, Hotamisligil GS (2002) Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity. Diabetes 51:1876–1883PubMed
22.
Xu H, Hirosumi J, Uysal KT, Guler AD, Hotamisligil GS (2002) Exclusive action of transmembrane TNF alpha in adipose tissue leads to reduced adipose mass and local but not systemic insulin resistance. Endocrinology 143:1502–1511CrossRefPubMed
23.
Cheung AT, Ree D, Kolls JK, Fuselier J, Coy DH, Bryer-Ash M (1998) An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha. Endocrinology 139:4928–4935PubMed
24.
Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R (1996) Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881–885PubMed
25.
Moller DE (2000) Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 11:212–217
26.
Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745–E751PubMed
27.
Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB (1995) The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95:2111–2119PubMed
28.
Okuno A, Tamemoto H, Tobe K et al. (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354–1361PubMed
29.
Sewter CP, Digby JE, Blows F, Prins J, O’Rahilly S (1999) Regulation of tumour necrosis factor-alpha release from human adipose tissue in vitro. J Endocrinol 163:33–38PubMed
30.
Orban Z, Remaley AT, Sampson M, Trajanoski Z, Chrousos GP (1999) The differential effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and cytokines in man. J Clin Endocrinol Metab 84:2126–2133
31.
Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM (1996) Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274:1377–1379CrossRefPubMed
32.
Zilberfarb V, Siquier K, Strosberg AD, Issad T (2001) Effect of dexamethasone on adipocyte differentiation markers and tumour necrosis factor-alpha expression in human PAZ6 cells. Diabetologia 44:377–386PubMed
33.
Chen XL, Lee K, Hartzell DL et al. (2001) Adipocyte insensitivity to insulin in growth hormone-transgenic mice. Biochem Biophys Res Commun 283:933–937CrossRefPubMed
34.
Ikeda A, Chang KT, Matsumoto Y et al. (1998) Obesity and insulin resistance in human growth hormone transgenic rats. Endocrinology 139:3057–3063
35.
Bulow B, Ahren B, Erfurth EM (2001) Increased leptin and tumour necrosis factor alpha per unit fat mass in hypopituitary women without growth hormone treatment. Eur J Endocrinol 145:737–742PubMed
36.
Mohamed-Ali V, Goodrick S, Rawesh A et al. (1997) Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196–4200PubMed
37.
Nonogaki K, Fuller GM, Fuentes NL et al. (1995) Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 136:2143–2149
38.
Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–3399PubMed
39.
Rotter V, Nagaev I, Smith U (2002) Interleukin-6 (IL-6) reduces gene and protein expression of IRS-1 and GLUT4 and is overexpressed in human fat cells from insulin-resistant subjects. Diabetes 51 [Suppl 2]: A303 (Abstract)
40.
Stith RD, Luo J (1994) Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock 44:210–215PubMed
41.
Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP (1997) Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 82:4167–4170PubMed
42.
Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 9:414–417PubMed
43.
Pickup JC, Mattock MB, Chusney GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286–1292CrossRefPubMed
44.
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334PubMed
45.
Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI (2002) Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679–684CrossRefPubMed
46.
Fasshauer M, Klein J, Lossner U, Paschke R (2003) Interleukin (IL)-6 mRNA expression is stimulated by insulin, isoproterenol, tumour necrosis factor alpha, growth hormone, and IL-6 in 3T3-L1 adipocytes. Horm Metab Res 35:147–152CrossRefPubMed
47.
Mohamed-Ali V, Flower L, Sethi J et al. (2001) beta-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab 86:5864–5869
48.
Path G, Bornstein SR, Gurniak M, Chrousos GP, Scherbaum WA, Hauner H (2001) Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function. J Clin Endocrinol Metab 86:2281–2288PubMed
49.
Vicennati V, Vottero A, Friedman C, Papanicolaou DA (2002) Hormonal regulation of interleukin-6 production in human adipocytes. Int J Obes Relat Metab Disord 26:905–911CrossRef
50.
Fried SK, Bunkin DA, Greenberg AS (1998) Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847–850
51.
Papanicolaou DA, Petrides JS, Tsigos C et al. (1996) Exercise stimulates interleukin-6 secretion: inhibition by glucocorticoids and correlation with catecholamines. Am J Physiol 271:E601–E605PubMed
52.
Andrews RC, Walker BR (1999) Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Colch) 96:513–523
53.
Sesmilo G, Biller BM, Llevadot J et al. (2000) Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 133:111–122PubMed
54.
Grunfeld C, Feingold KR (1991) The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 3:143–158PubMed
55.
Steppan CM, Bailey ST, Bhat S et al. (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312CrossRefPubMed
56.
Steppan CM, Brown EJ, Wright CM et al. (2001) A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 98:502–506CrossRefPubMed
57.
Rajala MW, Obici S, Scherer PE, Rossetti L (2003) Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 111:225–230CrossRefPubMed
58.
Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM (2002) Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 10:1–5PubMed
59.
Nagaev I, Smith U (2001) Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 285:561–564CrossRefPubMed
60.
Way JM, Gorgun CZ, Tong Q et al. (2001) Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 276:25651–25653PubMed
61.
Le Lay S, Boucher J, Rey A et al. (2001) Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem Biophys Res Commun 289:564–567CrossRefPubMed
62.
Juan CC, Au LC, Fang VS et al. (2001) Suppressed gene expression of adipocyte resistin in an insulin-resistant rat model probably by elevated free fatty acids. Biochem Biophys Res Commun 289:1328–1333CrossRefPubMed
63.
Milan G, Granzotto M, Scarda A et al. (2002) Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss. Obes Res 10:1095–1103
64.
Fukui Y, Motojima K (2002) Expression of resistin in the adipose tissue is modulated by various factors including peroxisome proliferator-activated receptor alpha. Diabetes Obes Metab 4:342–345CrossRefPubMed
65.
Shojima N, Sakoda H, Ogihara T et al. (2002) Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 51:1737–1744PubMed
66.
Haugen F, Jorgensen A, Drevon CA, Trayhurn P (2001) Inhibition by insulin of resistin gene expression in 3T3-L1 adipocytes. FEBS Lett 507:105–108CrossRefPubMed
67.
Moore GB, Chapman H, Holder JC et al. (2001) Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice. Biochem Biophys Res Commun 286:735–741CrossRefPubMed
68.
Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2001) Isoproterenol inhibits resistin gene expression through a G(S)-protein-coupled pathway in 3T3-L1 adipocytes. FEBS Lett 500:60–63CrossRefPubMed
69.
Kim KH, Lee K, Moon YS, Sul HS (2001) A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 276:11252–11256CrossRefPubMed
70.
Zhong Q, Lin CY, Clarke KJ, Kemppainen RJ, Schwartz DD, Judd RL (2002) Endothelin-1 inhibits resistin secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 296:383–387CrossRefPubMed
71.
Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2001) Tumor necrosis factor alpha is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 288:1027–1031CrossRefPubMed
72.
Delhanty PJ, Mesotten D, McDougall F, Baxter RC (2002) Growth hormone rapidly induces resistin gene expression in white adipose tissue of spontaneous dwarf (SDR) rats. Endocrinology 143:2445–2448
73.
Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K (1996) cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286–289PubMed
74.
Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746–26749PubMed
75.
Hu E, Liang P, Spiegelman BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697–10703PubMed
76.
Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M (1996) Isolation and characterization of GBP28, a novel gelatin-binding protein. J Biochem (Tokyo) 120:803–812
77.
Fruebis J, Tsao TS, Javorschi S et al. (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005–2010PubMed
78.
Yamauchi T, Kamon J, Waki H et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946PubMed
79.
Yamauchi T, Kamon J, Minokoshi Y et al. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295CrossRefPubMed
80.
Tomas E, Tsao TS, Saha AK et al. (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99:16309–16313CrossRefPubMed
81.
Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953PubMed
82.
Maeda N, Shimomura I, Kishida K et al. (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731–737PubMed
83.
Kubota N, Terauchi Y, Yamauchi T et al. (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863–25866CrossRefPubMed
84.
Ma K, Cabrero A, Saha PK et al. (2002) Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 277:34658–34661CrossRefPubMed
85.
Yamauchi T, Kamon J, Waki H et al. (2003) Globular adiponectin protected ob/ob mice from diabetes and apoE deficient mice from atherosclerosis. J Biol Chem 278:2461–2468CrossRefPubMed
86.
Spranger J, Kroke A, Mohlig M et al. (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–228CrossRef
87.
Yamauchi T, Kamon J, Ito Y et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769CrossRefPubMed
88.
Weyer C, Funahashi T, Tanaka S et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935PubMed
89.
Hotta K, Funahashi T, Arita Y et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599PubMed
90.
Yang WS, Lee WJ, Funahashi T et al. (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815–3819PubMed
91.
Hulver MW, Zheng D, Tanner CJ et al. (2002) Adiponectin is not altered with exercise training despite enhanced insulin action. Am J Physiol Endocrinol Metab 283:E861–E865PubMed
92.
Maeda N, Takahashi M, Funahashi T et al. (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094–2099PubMed
93.
Yu JG, Javorschi S, Hevener AL et al. (2002) The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968–2974PubMed
94.
Motoshima H, Wu X, Sinha MK et al. (2002) Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87:5662–5667CrossRefPubMed
95.
Yang WS, Jeng CY, Wu TJ et al. (2002) Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376–380PubMed
96.
Combs TP, Wagner JA, Berger J et al. (2002) Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143:998–1007
97.
Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2001) Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 507:142–146PubMed
98.
Delporte ML, Funahashi T, Takahashi M, Matsuzawa Y, Brichard SM (2002) Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies. Biochem J 367:677–685CrossRefPubMed
99.
Fasshauer M, Kralisch S, Klier M et al. (2003) Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 301:1045–1050CrossRefPubMed
100.
Kappes A, Loffler G (2000) Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res 32:548–554PubMed
101.
Staiger H, Tschritter O, Kausch C, Lammers R, Stumvoll M, Haring HU (2002) Human serum adiponectin levels are not under short-term negative control by free fatty acids in vivo. Horm Metab Res 34:601–603CrossRefPubMed
102.
Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2002) Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290:1084–1089CrossRefPubMed
103.
Bluher M, Michael MD, Peroni OD et al. (2002) Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 3:25–38PubMed
104.
Viengchareun S, Zennaro MC, Pascual-Le TL, Lombes M (2002) Brown adipocytes are novel sites of expression and regulation of adiponectin and resistin. FEBS Lett 532:345–350CrossRefPubMed
105.
Halleux CM, Takahashi M, Delporte ML et al. (2001) Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 288:1102–1107PubMed
106.
Makimura H, Mizuno TM, Bergen H, Mobbs CV (2002) Adiponectin is stimulated by adrenalectomy in ob/ob mice and is highly correlated with resistin mRNA. Am J Physiol Endocrinol Metab 283:E1266–E1271
107.
Masuzaki H, Paterson J, Shinyama H et al. (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166–2170PubMed
108.
Nishizawa H, Shimomura I, Kishida K et al. (2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734–2741PubMed
109.
Ahima RS, Flier JS (2000) Leptin. Annu Rev Physiol 62:413–437
110.
Kellerer M, Lammers R, Fritsche A et al. (2001) Insulin inhibits leptin receptor signalling in HEK293 cells at the level of janus kinase-2: a potential mechanism for hyperinsulinaemia-associated leptin resistance. Diabetologia 44:1125–1132CrossRefPubMed
111.
Fernandez-Galaz C, Fernandez-Agullo T, Perez C et al. (2002) Long-term food restriction prevents ageing-associated central leptin resistance in wistar rats. Diabetologia 45:997–1003CrossRef
112.
Ahima RS, Flier JS (2000) Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11:327–332PubMed
113.
Hallakou S, Doare L, Foufelle F et al. (1997) Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46:1393–1399PubMed
114.
Zhang B, Graziano MP, Doebber TW et al. (1996) Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 271:9455–9459PubMed
115.
Kallen CB, Lazar MA (1996) Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 93:5793–5796PubMed
116.
De Vos P, Lefebvre AM, Miller SG et al. (1996) Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 98:1004–1009PubMed
117.
Mantzoros CS, Qu D, Frederich RC, Susulic VS et al. (1996) Activation of beta(3) adrenergic receptors suppresses leptin expression and mediates a leptin-independent inhibition of food intake in mice. Diabetes 45:909–914PubMed
118.
Slieker LJ, Sloop KW, Surface PL et al. (1996) Regulation of expression of ob mRNA and protein by glucocorticoids and cAMP. J Biol Chem 271:5301–5304CrossRefPubMed
119.
Rentsch J, Chiesi M (1996) Regulation of ob gene mRNA levels in cultured adipocytes. FEBS Lett 379:55–59PubMed
120.
Hardie LJ, Rayner DV, Holmes S, Trayhurn P (1996) Circulating leptin levels are modulated by fasting, cold exposure and insulin administration in lean but not Zucker (fa/fa) rats as measured by ELISA. Biochem Biophys Res Commun 223:660–665
121.
Saladin R, De Vos P, Guerre-Millo M et al. (1995) Transient increase in obese gene expression after food intake or insulin administration. Nature 377:527–529PubMed
122.
De Vos P, Saladin R, Auwerx J, Staels B (1995) Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake. J Biol Chem 270:15958–15961PubMed
123.
Willi SM, Kennedy A, Wallace P, Ganaway E, Rogers NL, Garvey WT (2002) Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin. Diabetes 51:2895–2902PubMed
124.
Asada N, Takahashi Y, Honjo M (2000) Effects of 22K or 20K human growth hormone on lipolysis, leptin production in adipocytes in the presence and absence of human growth hormone binding protein. Horm Res 54:203–207CrossRefPubMed
125.
Norrelund H, Gravholt CH, Englaro P et al. (1998) Increased levels but preserved diurnal variation of serum leptin in GH-deficient patients: lack of impact of different modes of GH administration. Eur J Endocrinol 138:644–652PubMed
126.
Brennan BM, Rahim A, Blum WF, Adams JA, Eden OB, Shalet SM (1999) Hyperleptinaemia in young adults following cranial irradiation in childhood: growth hormone deficiency or leptin insensitivity? Clin Endocrinol (Oxf) 50:163–169
127.
Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T (1998) Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 83:3476–3479PubMed
128.
Damjanovic SS, Petakov MS, Raicevic S et al. (2000) Serum leptin levels in patients with acromegaly before and after correction of hypersomatotropism by trans-sphenoidal surgery. J Clin Endocrinol Metab 85:147–154PubMed
Metadata
Title
Regulation of adipocytokines and insulin resistance
Authors
M. Fasshauer
Dr. R. Paschke
Publication date
01-12-2003
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2003
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1228-z

Other articles of this Issue 12/2003

Diabetologia 12/2003 Go to the issue

Article

Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats

Observation

Absence of association between SPINK1 trypsin inhibitor mutations and Type 1 or 2 diabetes mellitus in India and Germany

Article

Rosiglitazone produces insulin sensitisation by increasing expression of the insulin receptor and its tyrosine kinase activity in brown adipocytes

Article

Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats

Comment

To: Rippin JD, Patel A, Belyaev ND, Gill GV, Barnett AH, Bain SC (2003) Nitric oxide synthase gene polymorphisms and diabetic nephropathy. Diabetologia 46:426–428

Comment

—to: Rippin JD, Patel A, Belyaev ND, Gill GV, Barnett AH, Bain SC (2003) Nitric oxide synthase gene polymorphisms and diabetic nephropathy. Diabetologia 46:426–428
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits